Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 31Carcinoma, Hepatocellular 30Neoplasms 19Carcinoma, Renal Cell 16Melanoma 10Carcinoma, Non-Small-Cell Lung 10Thyroid Neoplasms 9Endometrial Neoplasms 9Squamous Cell Carcinoma of Head and Neck 6Colorectal Neoplasms 5Triple Negative Breast Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Liver Neoplasms 4Carcinoma, Transitional Cell 4Uterine Cervical Neoplasms 3Small Cell Lung Carcinoma 3Recurrence 3Lymphoma 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Carcinoma 3Biliary Tract Neoplasms 3Stomach Neoplasms 2Solid Tumors 2Osteosarcoma 2Lung Neoplasms 2Kidney Neoplasms 2Glioma 2Diabetes Mellitus, Insulin-Dependent, 12 2

Interventions

tanespimycin 2pembrolizumab 2parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2zanidatamab 1tislelizumab 1spartalizumab 1sitravatinib 1repaglinide 1pemigatinib 1pamiparib 1liposomal doxorubicin 1lenvatinib 1epothilone B 1drospirenone 1cabiralizumab 1Temozolomide 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1HMPL-013 1Gemcitabine 1Ethinyl Estradiol 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Advanced Malignancies × lenvatinib × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡